PRISM MarketView

Inside Look: Investors Await Earnings for PRISM Consumer Products Index

New York, April 29, 2024 - PRISM MarketView - Over 40% of the S&P 500 has now reported quarterly earnings as key Q1 earnings beat metrics are trending above average. However, last week Q1 GDP illustrated slower than expected economic growth citing a 1.6% increase whi...

29 April 2024

Biodexa Secures Rights to Commercialize eRapa for Rare Cancer, Additional Indications

New York, April 29, 2024 - PRISM MarketView - Biodexa Pharmaceuticals (Nasdaq: BDRX) has entered an agreement with Emtora Biosciences (Rapamycin Holdings Inc.) for the rights to eRapa under an exclusive, worldwide license to develop, manufacture, commercialize and advanc...

29 April 2024

Holidaze Season: Green Successes Cited by Most Cannabis Retailers On 4/20

New York, April 26, 2024 - PRISM MarketView - U.S. cannabis retailers saw strong sales on April 20, the peak day for cannabis purchases, despite challenges from widespread e-commerce platform outages.

26 April 2024

Vistagen Tackles Mental Fatigue with Investigational Nasal Spray

New York, April 26, 2024 - PRISM MarketView - Biopharmaceutical company, Vistagen (Nasdaq: VTGN), is tackling mental fatigue with PH15, an investigational pherine nasal spray. The company has reported positive results from a Phase 2a pilot study of PH15, which has demons...

26 April 2024

Talkspace Expands Mental Health Offering to Additional Half Million Women

New York, April 26, 2024 - PRISM MarketView - Behavioral health company, Talkspace (Nasdaq: TALK) will expand its comprehensive mental health offering to an additional 500,000 women through a partnership with speciality telemedicine company, Thirty Madison. The partnersh...

26 April 2024

Capricor Therapeutics Advances Duchenne Muscular Dystrophy Candidate

New York, April 26, 2024 - PRISM MarketView - Capricor Therapeutics (Nasdaq: CAPR) has successfully completed a Type-B Chemistry, Manufacturing and Controls (CMC) meeting with the FDA to discuss next steps for the company’s Biologics License Application (BLA) submission ...

26 April 2024

Positive Topline Results for Immutep’s Head and Neck Cancer Treatment

New York, April 26, 2024 - PRISM MarketView - Immutep Limited (Nasdaq: IMMP) has reported positive preliminary topline results from Cohort B of its TACTI-003 Phase 2b trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) as first-line tr...

26 April 2024

AI Drug Discovery Predictive Oncology Leads PRISM NextGen Tech and AI Index on Ovarian Cancer Abstract Acceptance

New York, April 25, 2024 - PRISM MarketView - Predictive Oncology Inc. (POAI) has announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago. The meeting will take place from May 31st – June 4...

25 April 2024

BioStem Technologies Prepares to Uplist to Senior Exchange

New York, April 25, 2024 - PRISM MarketView - BioStem Technologies (OTC: BSEM) has completed a two year audit as part of its preparations for uplisting to a senior stock exchange. The company announced today that it anticipates its uplisting will help to further validate...

25 April 2024

SKYX Enters Strategic Partnership with World-Leading Lighting Supplier Opening Access to US, Chinese, and European Markets

New York, April 25, 2024 - PRISM MarketView - Disruptive smart platform technology company, SKYX (Nasdaq: SKYX) has increased its access to professional and retail customers in US, Chinese and European markets after entering an important new partnership with the world-le...

25 April 2024